← Back to Search

Anti-Parkinson's Agent

GOCOVRI for Parkinson's Disease

Phase 4
Waitlist Available
Led By Amie Hiller, MD
Research Sponsored by Oregon Health and Science University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks
Awards & highlights

Study Summary

This trial will study the effects of Amantadine on patients with Parkinson's disease who are also experiencing involuntary movements.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Total amount of activity per day
Secondary outcome measures
Change in International Physical Activity Questionnaire
Change in Movement Disorders Society - Unified Dyskinesia Rating Scale
Change in Parkinson's Disease Questionnaire 39 Score
+4 more

Side effects data

From 2015 Phase 3 trial • 126 Patients • NCT02136914
29%
Hallucination, any type
24%
Oedema peripheral
24%
Hallucination, visual
22%
Dizziness
17%
Dry mouth
16%
Fall
14%
Constipation
11%
Urinary tract infection
10%
Anxiety
10%
Contusion
10%
Livedo reticularis
8%
Hallucination, auditory
6%
Abnormal dreams
6%
Depression
6%
Headache
5%
Back pain
3%
Balance disorder
2%
Cellulitis
2%
Musculoskeletal pain
2%
Hip fracture
2%
Subdural haematoma
2%
ON and OFF phenomenon
2%
Encephalopathy
2%
Humerus fracture
2%
Muscular weakness
2%
Small intestinal obstruction
2%
Presyncope
2%
Nasopharyngitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
ADS-5102 (340 mg)

Trial Design

1Treatment groups
Experimental Treatment
Group I: GOCOVRI TreatmentExperimental Treatment1 Intervention
All participants will have gait, balance, dyskinesia assessed before and after receiving GOCOVRI (274 mg/day).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GOCOVRI
2020
Completed Phase 4
~10

Find a Location

Who is running the clinical trial?

Oregon Health and Science UniversityLead Sponsor
973 Previous Clinical Trials
6,846,021 Total Patients Enrolled
Adamas Pharmaceuticals, Inc.Industry Sponsor
10 Previous Clinical Trials
1,775 Total Patients Enrolled
Amie Hiller, MDPrincipal Investigator - Oregon Health and Science University
Oregon Health and Science University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease
Amie Hiller, MD 2020. "Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04387773.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top